 | This article has multiple issues. Please helpimprove it or discuss these issues on thetalk page.(Learn how and when to remove these messages) (Learn how and when to remove this message)
|
Pekka Sillanaukee (born 1964,TampereFinland) is a Finnishhealth technology entrepreneur.[1] Pekka graduated asan organic chemist in 1989, he became a Ph.D. in 1992 and was appointed Docent of Medical Biochemistry at the Faculty of Medicine of theUniversity of Tampere in 1993. Pekka has been a co-author of approximately 120 scientific original articles,[2] reviews or summaries. His scientific work has focused on clinical and medical biochemistry, alcohol, brain and cardiovascular related diseases, and development of laboratory-diagnostic tests and processes. He also has four international patents.[3][4][5][6]
Pekka has worked as a researcher at the Medical School of the University of Tampere and at Tampere University Hospital, as a responsible clinical researcher at Alko's research laboratories from 1987 to 1993, then as a director and business unit member at Pharmacia & Upjohn Inc. (Pfizer) 1994–1999, CEO at FIT Biotech Plc 1999–2004, and thereafter as an entrepreneur, co-founder or co-owner of different Finnish, Swedish and Estonian health technology and service companies including Bioretec Ltd, ESO International Ltd, Innokas Medical Ltd, Nordic Senior Services Ltd, Nova Vita Ltd, OS-Service, Ovumia Ltd, Palvelutähti Ltd, Paavolankoti Ltd, and Quattromed Ltd.
Since 2014 Sillanaukee has focused on the development offertility treatment technologies and practices in Ovumia Fertility Clinic.[7]
M.Sc.,University of Jyväskylä, Natural Science Faculty, Dep. of Chemistry and Dep. of Cell Biology, 1989.
Ph.D.,University of Tampere, Medical Faculty, Dep. of Biomedical Science, 1992.
Assistant Professorship (docent) of Medical Biochemistry, Medical Faculty, University of Tampere, Tampere, 1993. Qualification for Assistant Professorship (docent) inKarolinska Institute, Stockholm, Sweden, 1998.
Business & Executive management studies inHelsinki School of Economics and Business Administration 1993–1994,Stockholm School of Economics and Business Administration 1995–1998,London Business School 1998–1999,Aalto University 2011.
1) Use of sialic acid determination for determining alcohol consumption[6][8]
2) An improved method for diagnosing alcohol abuse[5]
3) Immunoassay and Kit for IgA Antibodies Specific for Acetaldehyde Adducts[4]
4) Immunochemical methods[3]
